eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 15
 
Share:
Share:
more
 
 
abstract:
Commentary

Pulmonary hypertension in left heart disease

Pratishtha Mehra, Vimal Mehta, Rishi Sukhija, Anjan K. Sinha, Mohit Gupta, M.P. Girish, Wilbert S. Aronow

Arch Med Sci 2019; 15, 1: 262–273
Online publish date: 2017/07/17
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Pulmonary hypertension in left heart disease (PH-LHD) is the most prevalent form of PH. It is classified as group 2 PH as per WHO classification. As the prevalence of left heart disease such as congestive heart failure is increasing, the number of patients with associated PH is rising, coupled with high morbidity and mortality. Pulmonary hypertension is initially passive or isolated post-capillary (Ipc-PH) due to increased left sided filling pressures. In long standing cases pre-capillary component is added due to development of pulmonary vascular disease, termed combined post- and pre-capillary PH (Cpc-PH) or reactive PH. We describe the hemodynamics, pathophysiology, role of echocardiography and right heart catheterization in PH-LHD. We discuss the significance of PH associated with congestive heart failure as well as valvular heart disease. Although there is no treatment for PH-LHD, we discuss and critically analyze various studies investigating the role of pulmonary vasodilators in this condition. As PH-LHD is an under studied disease, we highlight the areas where further research is required.
keywords:

pulmonary hypertension, left heart disease, congestive heart failure, pre-capillary, post-capillary, pulmonary artery pressure

references:
Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: 34-41.
Dupuis J, Guazzi M. Pathophysiology and clinical relevance of pulmonary remodeling in pulmonary hypertension due to left heart diseases. Can J Cardiol 2015; 31: 416-29.
Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53: 1119-26.
Fawzy ME, Hassan W, Stefadouros M, Moursi M, Shaer FE, Chaudhary MA. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis 2004; 13: 942-8.
Patel H, Desai M, Tuzcu EM, Griffin B, Kapadia S. Pulmonary hypertension in mitral regurgitation. J Am Heart Assoc 2014; 3: e000748.
Malouf JF, Sarano ME, Pellikka PA, et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 2002; 40: 789-95.
Khandhar S, Varadarajan P, Turk R, et al. Survival benefit of aortic valve replacement in patients with severe aortic regurgitation and pulmonary hypertension. Ann Thorac Surg 2009; 88: 752-7.
Abramson SV, Burke JF, Kelly Jr JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992; 116: 888-95.
Corte TJ, McDonagh TA, Wort SJ. Pulmonary hypertension in left heart disease: a review. Int J Cardiol 2012; 156: 253-8.
Fang JC, DeMarco T, Givertz MM, et al. World Health Organization Pulmonary Hypertension Group 2: pulmonary hypertension due to left heart disease in the adult – a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2012; 31: 913-33.
Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation 2012; 126: 975-90.
Vachiery J, Adir Y, Barberà J, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62: D100-8.
Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007; 99: 1146-50.
Badesch DB, Champion HC, Sanchez MAG, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-66.
Budev MM, Arroliga AC, Jennings CA. Diagnosis and evaluation of pulmonary hypertension. Cleve Clin J Med 2003; 70: S9-17.
Fox C, Kalarickal PL, Yarborowgh MJ, Jin JY. Perioperative management including new pharmacological vistas for patients with pulmonary hypertension for noncardiac surgery. Curr Opin Anaesthesiol 2008; 21: 467-72.
Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest 2013; 143: 758-66.
Tampakakis E, Leary PJ, Selby VN, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015; 3: 9-16.
Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67-119.
Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183-8.
Mehra MR, Canter CE, Hannan ME, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transpl 2016; 35: 1-23.
de Groote P, Asri CE, Fertin M, et al. Sildenafil in heart transplant candidates with pulmonary hypertension. Arch Cardiovasc Dis 2015; 108: 375-84.
Pons J, Leblanc MH, Bernier M, et al. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. J Heart Lung Transplant 2012; 31: 1281-7.
Sansone F, Rinaldi M. Oral sildenafil: potential role in heart transplantation. Review of the literature and personal experience. J Cardiol 2010; 55: 291-5.
Walls MC, Cimino N, Bolling SF, Bach DS. Persistent pulmonary hypertension after mitral valve surgery: does surgical procedure affect outcome? J Heart Valve Dis 2008; 17: 1-9.
Tracy GP, Proctor MS, Hizny CS. Reversibility of pulmonary artery hypertension in aortic stenosis after aortic valve replacement. Ann Thorac Surg 1990; 50: 89-93.
Dev V, Shrivastava S. Time course of changes in pulmonary vascular resistance and the mechanism of regression of pulmonary arterial hypertension after balloon mitral valvuloplasty. Am J Cardiol 1991; 67: 439-42.
Levine MJ, Weinstein JS, Diver DJ, et al. Progressive improvement in pulmonary vascular resistance after percutaneous mitral valvuloplasty. Circulation 1989; 79: 1061-7.
Li M, Dumesnil JG, Mathieu P, Pibarot P. Impact of valve prosthesis patient mismatch on pulmonary arterial pressure after mitral valve. J Am Coll Cardiol 2005; 45: 1034-40.
Puri S, Mehta V, Ahmed F, et al. Correlation of early functional capacity with biventricular function and residual pulmonary artery hypertension following mitral valve replacement surgery in patients with rheumatic mitral valve disease. J Cardiopulm Rehabil Prev 2013; 33: 244-8.
Nair KKM, Pillai HS, Titus T, et al. Persistent pulmonary artery hypertension in patients undergoing balloon mitral valvotomy. Pulm Circ 2013; 3: 426-31.
Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease. Incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol 2009; 53: 401-8.
Guazi M, Galie N. Pulmonary hypertension in left heart disease. Eur Respir Rev 2012; 21: 338-46.
Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125: 669-82.
Haworth SG, Hall SM, Patel M. Peripheral pulmonary vascular and airway abnormalities in adolescents with rheumatic mitral stenosis. Int J Cardiol 1998; 18: 405-16.
Kay JM, Edwards FR. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol 1973; 111: 239-45.
Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008; 14: 695-702.
Rhodes KM, Evemy K, Nariman S, Gibson GJ. Relation between severity of mitral valve disease and results of routine lung function tests in non-smokers. Thorax 1982; 37: 751-5.
Ibrahim E, Kassem A, Zakaria N. The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians. Egyptian J Chest Dis Tuberculosis 2012; 61: 495-500.
Calabro P, Limongelli G, Maddaloni V, et al. Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. Intern Emerg Med 2012; 7: 425-30.
Olson TP, Snyder EM, Frantz RP, Turner ST, Johnson BD. Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. Am Heart J 2007; 153: 426-32.
Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233-71.
Forfia PR, Vachiéry J. Echocardiography in pulmonary arterial hypertension. Am J Cardiol 2012; 110 (suppl): 16S-24S.
Bossone E, D’Andrea A, D’Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr 2013; 26: 1-14.
Howard LS, Grapsa J, Dawson D, et al. Echocardiographic assessment of pulmonary hypertension: standard operating procedure. Eur Respir Rev 2012; 21: 239-48.
McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 2797-802.
Masuyama T, Kodama K, Kitabatake A, Sato H, Nanto S, Inoue M. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation 1986; 74: 484-92.
Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011; 97: 612-22.
Amsallem M, Sternbach JM, Adigopula S, et al. Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. J Am Soc Echocardiogr 2016; 29: 93-102.
D’Alto M, Romeo E, Argiento P, et al. Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. J Am Soc Echocardiogr 2015; 28: 108-15.
Basil A, Liu T, Arkles J, et al. Serial changes in TAPSE correlate with functional assessment and clinical events in patients with PAH. Am J Respir Crit Care Med 2009; 179: A4882.
Paczynska M, Sobieraj P, Burzynski L, et al. Tricuspid annulus plane systolic excursion (TAPSE) has superior predictive value compared to right ventricular to left ventricular ratio in normotensive patients with acute pulmonary embolism. Arch Med Sci 2016; 12: 1008-14.
Sinha N, Devabhaktuni S, Kadambi A, et al. Can echocardiographically estimated pulmonary arterial elastance be a non-invasive predictor of pulmonary vascular resistance? Arch Med Sci 2014; 10: 692-700.
Gibbs S. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63 (Suppl II): 1-41.
Fox BD, Shimony A, Langleben D, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013; 42: 1083-91.
Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. Pulmonary hypertension in valvular heart disease. A comprehensive review on pathophysiology to therapy from the HAVEC group. JACC Cardiovasc Imaging 2015; 8: 83-99.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: e57-185.
Li M, Déry JP, Dumesnil JG, Boudreault JR, Jobin J, Pibarot P. Usefulness of measuring net atrioventricular compliance by Doppler echocardiography in patients with mitral stenosis. Am J Cardiol 2005; 96: 432-5.
Schwammenthal E, Vered Z, Agranat O, Kaplinsky E, Rabinowitz B, Feinberg MS. Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study. Circulation 2000; 102: 2378-84.
Brochet E, Detaint D, Fondard O, et al. Early hemodynamic changes versus peak values: what is more useful to predict occurrence of dyspnea during stress echocardiography in patients with asymptomatic mitral stenosis? J Am Soc Echocardiogr 2011; 24: 392-8.
Kapoor N, Varadarajan P, Pai RG. Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis. Eur J Echocardiogr 2008; 9: 31-3.
Faggiano P, Antonini-Canterin F, Ribichini F, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 2000; 85: 204-8.
Olaf S, Brala D, Ricarda B, et al. Exercise tolerance in asymptomatic patients with moderate-severe valvular heart disease and preserved ejection fraction. Arch Med Sci 2012; 8: 1018-26.
Magne J, Lancellotti P, Pierard LA. Exercise testing in asymptomatic severe aortic stenosis. JACC Cardiol Imaging 2014; 7: 188-99.
Marechaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J 2010; 31: 1390-7.
Lancellotti P, Magne J, Donal E, et al. Determinants and prognostic significance of exercise pulmonary hypertension in asymptomatic severe aortic stenosis. Circulation 2012; 126: 851-9.
Magne J, Lancellotti P, Pierard LA. Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation 2010; 122: 33-41.
Magne J, Donal E, Mahjoub H, et al. Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation. Heart 2015; 101: 391-6.
Heyning CMV, Magne J, Lancellotti P, Pierard LA. The importance of exercise echocardiography for clinical decision making in primary mitral regurgitation. J Cardiovasc Med 2012; 13: 260-5.
Lancellotti P, Gerard PL, Pierard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J 2005; 26: 1528-32.
Pierard LA, Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med 2004; 351: 1627-34.
McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-44.
Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction. JAMA 2013; 309: 1268-77.
Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780-5.
Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-6.
Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42: 140-7.
Louis A, Cleland JGF, Crabbe S, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-7.
Spieker LE, Mitrovic V, Noll G, et al. Acute hemodynamic and neurohumoral effects of selective ET-A receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 2000; 35: 1745-52.
Coletta AP, Cleland JGF. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001; 3: 747-50.
O’Connor CM, Gattis WA, Adams KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes, results of the randomized intravenous tezosentan study (RITZ-4). J Am Coll Cardiol 2003; 41: 1452-7.
Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: Randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. A prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003; 41: 204-10.
McMurray JJV, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009-19.
Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11: 12-20.
Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-62.
Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127: 1647-53.
Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart J 1997; 134: 44-54.
Guazzi M, Tumminello G, Marco FD, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44: 2339-48.
Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263-73.
Bonderman D, Ghio S, Felix SB, et al.; the Left ventricular systolic dysfunction associated with Pulmonary Hypertension riociguat Trial (LEPHT) study group. Riociguat for patients with pulmonary hypertension due to systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo controlled, dose-ranging hemodynamic study. Circulation 2013; 128: 502-11.
Gurtu V, Michelakis ED. Emerging therapies and future directions in pulmonary arterial hypertension. Can J Cardiol 2015; 31: 489-501.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe